reports
EQS-News: FUCHS acquires IRMCO® - Manufacturer of metal forming lubric...
EQS-News: FUCHS SE / Key word(s): Acquisition FUCHS acquires IRMCO® - Manufacturer of metal forming lubricants 02.04.2025 / 09:03 CET/CEST The issuer is solely responsible for the content of this announcement. FUCHS acquires IRMCO® - Manufacturer of metal forming lubricants Mannheim/Germany, April 2, 2025 – On April 1, the FUCHS Group, which operates globally in the lubricants industry acquired the US lubricants company IRMCO® Advanced Metalforming Lubricant Technologies, a manufacturer of metal-forming lubricants for demanding manufacturing processes. The family-run com...
EQS-News: FUCHS übernimmt IRMCO® – Spezialist für Schmierstofflösungen...
EQS-News: FUCHS SE / Schlagwort(e): Ankauf FUCHS übernimmt IRMCO® – Spezialist für Schmierstofflösungen in der Metallumformung 02.04.2025 / 09:03 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. FUCHS übernimmt IRMCO® – Spezialist für Schmierstofflösungen in der Metallumformung Mannheim, 2. April 2025 – Die weltweit im Schmierstoffbereich tätige FUCHS-Gruppe hat zum 1. April das US-amerikanische Schmierstoffunternehmen IRMCO® übernommen – einen Hersteller von Metallumformungsschmierstoffen für anspruchsvolle Fertigungsprozesse. Das ...
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innov...
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations Dr. Simone Steiner will focus on improving the manufacturing processes of individualized immunotherapies based on myvac® platform Strasbourg, France, April 1, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Simone Steiner, PhD, as Chief Technical Officer (CTO), effective immediately. Dr. Steiner will be responsible for manufacturing and process development for...
Transgene recrute une Directrice des opérations techniques (CTO) pour ...
Transgene recrute une Directrice des opérations techniques (CTO) pour accélérer le développement de ses innovations Le Dr Steiner poursuivra l’amélioration des procédés de fabrication des immunothérapies individualisées issues de la plateforme myvac® Strasbourg, France, le 1er avril 2025, 17 h 45 — Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, annonce la nomination de Simone Steiner, PhD, en tant que Directrice des opérations techniques (CTO), à compter de ce jour. Le Dr Steiner s...
- Andreas Riemann
- Jean Danjou
- Marc Lavaud
- Youssef Besbes
ZIL2 ELRINGKLINGER AG
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
CGM CEGEDIM SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
SESL SES-IMAGOTAG SA
XIL XILAM ANIMATION SA
ALR ALIOR BANK SA
JUN3 JUNGHEINRICH AG PREF
DMP DERMAPHARM HOLDING SE
TGN SOCIETATEA NATIONALA DE TRANSPORT GAZE NATURALE TRANSGAZ S.A.
VOS VOSSLOH AG
2CRSI 2CRSI SA
GRE GRENERGY RENOVABLES
CLA CLARANOVA SE
SFQ SAF-HOLLAND SE
MRX MISTER SPEX SE
ENER GRUPO ECOENER S.A.
LOUP SOCIETE L.D.C.
- Andreas Riemann
- Jean Danjou
- Marc Lavaud
- Youssef Besbes
ZIL2 ELRINGKLINGER AG
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
HCO HIGHCO SA
CGM CEGEDIM SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
SESL SES-IMAGOTAG SA
XIL XILAM ANIMATION SA
ALR ALIOR BANK SA
JUN3 JUNGHEINRICH AG PREF
DMP DERMAPHARM HOLDING SE
TGN SOCIETATEA NATIONALA DE TRANSPORT GAZE NATURALE TRANSGAZ S.A.
VOS VOSSLOH AG
2CRSI 2CRSI SA
GRE GRENERGY RENOVABLES
CLA CLARANOVA SE
SFQ SAF-HOLLAND SE
MRX MISTER SPEX SE
ENER GRUPO ECOENER S.A.
LOUP SOCIETE L.D.C.
- Martial Descoutures
- Oussema Denguir
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Martial Descoutures
- Oussema Denguir
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of...
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025 2024 Full-year results and business update Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part expected in Q2 2025 Randomization in Phase II part of the Phase I/II trial evaluating TG4050 in head and neck cancer patients due to be completed in Q4 2025 New trial with individualized cancer vaccine p...
Transgene franchit des étapes clés en 2024, avec la preuve de principe...
Transgene franchit des étapes clés en 2024, avec la preuve de principe clinique de son vaccin individualisé contre le cancer Perspectives prometteuses pour 2025 Résultats annuels 2024 et point sur l’activité Obtention de la preuve de principe clinique du vaccin thérapeutique individualisé TG4050 dans l’étude de Phase I en situation adjuvante des cancers de la tête et du cou - Nouvelles données attendues au deuxième trimestre 2025 avec le suivi de tous les patients inclus dans la Phase I, à 24 mois Fin de la randomisation dans la partie Phase II de l’essai clinique de Phase I/II de TG...
- Saïma Hussain
IDI: Private equity access with shareholder focus
IDI: Private equity access with shareholder focus EARNINGS/SALES RELEASES In a challenging 2024, IDI remained selective yet resilient, prioritising quality over volume with eight strategic deals, including stakes in Capexsto and TTK. While this measured approach weighed on net income, it reflected IDI’s disciplined investment strategy—waiting for the right opportunities, not just any. With €346m ready to deploy, IDI remained poised for action. A €1.4 extraordinary dividend reinforced its unwav...
- Amira Manai
- Amira Manai
- Bruno Cavalier
- Michael B. Schäfer
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
TIETO TIETOEVRY OYJ
LPP LPP S.A.
PAT PATRIZIA AG
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
FPE3 FUCHS PETROLUB SE
DSPW DOOSAN SKODA POWER A.S.
HBX HBX GROUP INTERNATIONAL PLC
- Bruno Cavalier
- Michael B. Schäfer
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
TIETO TIETOEVRY OYJ
LPP LPP S.A.
PAT PATRIZIA AG
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
FPE3 FUCHS PETROLUB SE
DSPW DOOSAN SKODA POWER A.S.
HBX HBX GROUP INTERNATIONAL PLC
- Michael B. Schäfer
- Michael B. Schäfer
- Michael B. Schäfer
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.